He had a malignant mole remove last year. It was a nodal one and 3mm so there did a wide area excision. From then on he had a 3-monthly skin check and ultrasound. In Aug this year he discovered another dodgy mole, it was .7mm and was removed. Between them deciding if another WAE was needed, it was discovered that he had a slightly swollen lymph node in his armpit. A biopsy was done and melanoma found. He went in 3 weeks ago and had them all removed.
I’m caring for a person who has been diagnosed with stage 3 melanoma and would like to hear of people’s experiences with immunotherapy. Here’s what has happened so far.
I’m being as supportive as I can but I can’t make this decision for him. I trying to get as much information for him so he can decide. Any advice, guidance, sharing of your own experiences would be a tremendous help.
Yesterday we met with the oncologist, who said melanoma had been found in 2 out of 15 nodes. His CTI scan and MRI found no other evidence of spread. They have therefore recommended immunotherapy, specifically Nivolumab (Opdivo), which he was would have once a month. It’s that or continue with surveillance, i.e. skin check, ultrasound, and CTI every 3 months.
We are going back in early Jan to discuss further and give them a decision.
Methods: Murine B16F10 melanoma tumors were established subcutaneously in C57BL/6 mice. Mice were then treated with intraperitoneal injections of vehicle twice per week (control-group 1, n = 6), Cisplatin 5 mg/kg/wk (group 2; n = 6), and Cannabidiol (CBD) 5 mg/kg twice per week (group 3; n = 6). Tumors were measured and volume calculated as (4π/3) × (width/2) 2 × (length/2). Tumor size and survival curves were measured. Results were compared using a one-way ANOVA with multiple comparison test.
Background: Malignant melanoma is a complex malignancy with significant morbidity and mortality. The incidence continues to rise, and despite advances in treatment, the prognosis is poor. Thus, it is necessary to develop novel strategies to treat this aggressive cancer. Synthetic cannabinoids have been implicated in inhibiting cancer cell proliferation, reducing tumor growth, and reducing metastasis. We developed a unique study focusing on the effects of treatment with a cannabinoid derivative on malignant melanoma tumors in a murine model.
Conclusions: We demonstrate a potential beneficial therapeutic effect of cannabinoids, which could influence the course of melanoma in a murine model. Increased survival and less tumorgenicity are novel findings that should guide research to better understand the mechanisms by which cannabinoids could be utilized as adjunctive treatment of cancer, specifically melanoma. Further studies are necessary to evaluate this potentially new and novel treatment of malignant melanoma.
Results: A significant decrease in tumor size was detected in mice treated with CBD when compared with the control group (P = 0.01). The survival curve of melanoma tumors treated with CBD increased when compared with the control group and was statistically significant (P = 0.04). The growth curve and survival curve of melanoma tumors treated with Cisplatin were significantly decreased and increased, respectively, when compared with the control and CBD-treated groups. Mice treated with Cisplatin demonstrated the longest survival time, but the quality of life and movement of CBD-treated mice were observed to be better.
Keywords: Cannabidiol; Cannabinoid; Medical Cannabis derivatives; Melanoma.